Navigation Links
GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
Date:11/11/2013

ght, Director of Research and Development at GW. "We believe this clinical program demonstrates the flexibility and broad application of GW's cannabinoid platform to treat significant, unmet therapeutic needs." 

This study is a 20-patient, multicentre, two part study with an open-label phase to assess safety and tolerability of GW cannabinoids in combination with temozolomide, and a double blind, randomised, placebo-controlled phase with patients randomised to active or placebo, and with a primary outcome measure of 6 month progression free survival. The study objective is to assess the tolerability, safety and pharmacodynamics of a mixture of two principal cannabinoids, THC and CBD in a 1:1 allocation ratio, in combination with temozolomide in patients with recurrent GBM. Secondary endpoints include additional pharmacokinetic and biomarker analyses and additional measurable outcomes of tumor response.

References:

i. Parolaro D, Massi P, Rubino T, Monti E. Endocannabinoids in the immune system and cancer. Prostaglandins Leukot Essent Fatty Acids 2002;66(2-3):319-32.
ii. Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003;3(10):745-55.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 22 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has established a world l
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... on electrons, but one of the most promising technologies ... based on light (photons) instead of electrons. First, it ... of single photons and control their direction. Researchers around ... achieve this control, but now scientists at the Niels ... of photons emitted one at a time and in ...
(Date:8/29/2014)... Pittsburgh, PA (PRWEB) August 29, 2014 ... Chairman, Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, ... JASIS on September 5, 2014. JASIS , Asia’s ... September 3-5, 2014, in Makuhari Messe, Japan. , ... New Tools for Bioanalysis from Single Molecules to Single ...
(Date:8/29/2014)... California (PRWEB) August 29, 2014 ... of Energy's 2014 Hydrogen Production R&D Award ... -- by splitting water using sunlight. , Shared ... (NREL) and the University of Nevada, Las Vegas ... work developing models of photoelectrochemical solar-hydrogen production and ...
(Date:8/29/2014)... August 29, 2014 Intrinsic Imaging, ... certified, GAMP® 5 compliant imaging core lab, announced ... Phase II clinical trial to assess a new ... this trial, Intrinsic Imaging will provide comprehensive imaging ... protocol and charter development, site qualification, site training ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Livermore Team Awarded for Hydrogen Production Research 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... cells is limited by a lack of methods for studying ... different methods, a team of Uppsala researchers have now provided ... on several levels at the same time. Their article is ... also show that the method can be used to determine ...
... decorative, flower-like defects in the nanomaterial graphene could have ... and mechanical properties, according to researchers at the National ... In a new paper,* the team for the first ... occur naturally or be induced to occur in graphene, ...
... of the March 11 earthquake and rolling blackouts that ... award-winning undergraduate internship program NanoJapan is scrambling to run ... U.S. undergraduates travel to Japan for lab internships, NanoJapan ... send 25-30 students to Rice University laboratories for three ...
Cached Biology Technology:Combo method reveals cells' signal systems 2Defect in graphene may present bouquet of possibilities 2Reverse NanoJapan: Rice to host 25-30 Japanese students 2
(Date:8/29/2014)... Researchers at UC Davis have made some surprising ... infection. Studying simian immunodeficiency virus (SIV), the team ... Paneth cells are early responders to viral invasion ... producing a cytokine called interleukin-1 beta (IL-1β). ... IL-1β causes breakdown of the gut epithelium that ...
(Date:8/29/2014)... the University of Texas Medical Branch at Galveston has gone ... can completely protect monkeys against a lethal dose of Ebola ... when the disease is severe. , Thomas Geisbert, professor of ... discussing advances in Ebola treatment research. The filoviruses known ... deadly of pathogens, with fatality rates of up to 90 ...
(Date:8/29/2014)... available in German . ... the natural nitrogen cycle on Earth and in biological ... thought to depend on nitrite as their source of ... Daims, a microbiologist at the University of Vienna, has ... an alternative source of energy. The oxidation of hydrogen ...
Breaking Biology News(10 mins):The early cost of HIV 2Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3
... nation,s Upper Midwest have changed greatly since the time ... coming. That,s according to research done by Lisa ... of Natural Resource Ecology and Management and her team ... entire ecosystem," said Schulte, whose research has recently been ...
... be lacking for perennial wheat to be grown on any ... Dr. Charlie Rush, Texas Agricultural Experiment Station plant pathologist., ... plant breeders, Rush is finding a groundswell of interest as ... on his perennial wheat study., Rush obtained his initial ...
... may occur, in part, because of a problem in an ... key chemical messenger in the brain, scientists have found in ... that the gene is turned on at increasingly high rates ... the brain involved in higher functions like thinking and decision-making ...
Cached Biology News:Upper Midwest forests are losing diversity, complexity, ISU study finds 2A wheat for all seasons -- and reasons 2A wheat for all seasons -- and reasons 3How schizophrenia develops: Major clues discovered 2
DTT, 25g...
...
...
Antibody specific for trimethyl-Lys27 of histone H3. Mouse monoclonal. Antigen: Synthetic peptide derived from histone H3, trimethylated at lysine 27...
Biology Products: